News and Announcements
Imagion Biosystems announces positive results of its clinical trial data
- Published February 16, 2023 6:52AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imagion Biosystems (ASX: IBX) released this week the results of an independent review of their clinical trial data, which confirms that the company’s targeted imaging agent is safe and detectable by MRI machines. The company also announced it has dosed 9 patients in its Phase 1 HER2 breast cancer study still open for enrollment in four sites across Australia.
Guided by the clinical results, Imagion has decided to prioritize the development of its targeted nanoparticles in conjuncture with the existing MRI technology, as opposed to IBX’s proprietary MRX machines. With this shift in strategy, the company hopes to eliminate the near-term expense and risks associated with developing and introducing a new type of detection technology.
The company held a webinar yesterday to discuss the announcement with shareholders. The recording can be viewed here.
Sharing the full announcement with you to see if we can get an inclusion in WI’s next newsletter. It would be great to include the link to the recording in the company blurb to drive traffic to the site.
Connect with the company and learn more about Imagion Biosystems by accessing their deal room here.
Company Updates
The A$20.4 Million Inertia Trap: How Kepa Software Is Unlocking Value in Enterprise Capital Allocation
A government agency renewed the same maintenance decision nine years running, because auditing the original choice was deemed too expensive. When the portfolio was finally tested, A$20.4 million of low value spend was identified in a single year. Kepa Software’s capital governance platform was built to expose and eliminate precisely these boardroom blind spots. For […]
Forget the share price. SpaceX just published a map of the next five years.
Most coverage of SpaceX’s result focused on a 9.1% share price fall. That is noise. The signal is in the transcript: compute, power, bandwidth and demand over the next five years.
The prefab company that deliberately leaves part of the house unbuilt
BuiltQuik prefabricates the floor and roof structure and stops there. Co-founder Ryan Mullaney argues the omission is the product. Prefabricated housing usually means a factory. A large central facility, identical modules, limited room to move on design, and a logistics problem getting the finished box to site. BuiltQuik builds the opposite, and the design decision […]
Backed By Leading Investment Groups and Family Offices
